<DOC>
	<DOCNO>NCT02850406</DOCNO>
	<brief_summary>This study consist two part , Part A Part B . Part A single dose PK study adolescent subject Sickle Cell Disease . Part B multiple dose safety , exploratory efficacy PK study adolescent Sickle Cell Disease subject .</brief_summary>
	<brief_title>Study Evaluate Effect GBT440 Adolescents With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>1 . Male female age 12 17 year age ( inclusive ) homozygous hemoglobin SS ( HbSS ) hemoglobin S beta0 thalassemia ( HbS β0 thal ) . 2 . A subject take hydroxyurea may enrol dose stable least 3 month anticipate need dose adjustment study sign hematological toxicity . 3 . Written inform parental/ guardian consent subject assent obtain per institutional review board ( IRB ) /Ethics Committee ( EC ) policy requirement , consistent International Council Harmonisation ( ICH ) guideline . 1 . Any one follow require medical attention within 14 day prior sign inform consent form ( ICF ) : Vasoocclusive crisis ( VOC ) Acute chest syndrome ( ACS ) Stroke Splenic sequestration crisis Dactylitis 2 . Requires chronic transfusion therapy 3 . History stroke meet criterion primary stroke prophylaxis ( history two Transcranial Doppler ( TCD ) measurement ≥ 200 cm/sec ) 4 . Transfusion within 30 day prior sign Informed Consent Form . 5 . Renal dysfunction require chronic dialysis creatinine ≥ 1.5 milligram per deciliter ( mg/dL ) 6 . History hepatic compromise severe liver disease 7 . Clinically relevant cardiac abnormality</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>